Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCyRuxo: Ruxolitinib for GVHD Prophylaxis
NCT04669210Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Nov 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Incidence of acute GVHD grade II-IV at 125 days. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04669210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669210.